Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.

Trial Profile

Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2013

At a glance

  • Drugs Spheramine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 21 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top